Moreover, blockade via anti-Nectin-2 monoclonal antibodies can induce antibody-dependent cellular cytotoxicity (ADCC) with robust anti-tumor response in breast and ovarian cancers, indicating its role in immune regulation (77, 78). This evidence concerns the gene NECTIN2 and ovarian cancer.